Invivyd (IVVD) Long-Term Deferred Tax (2023 - 2025)
Invivyd's (IVVD) quarterly Long-Term Deferred Tax came in at $253.0 million in Q4 2025, up 3.27% on a YoY basis from $244.9 million in Q4 2024, and up 3.27% quarter-over-quarter from $244.9 million in Q4 2024.
Analysis
Invivyd (IVVD) Long-Term Deferred Tax (2023 - 2025) Analysis & Trends
Invivyd (IVVD) has reported Long-Term Deferred Tax for 3 consecutive years, with $253.0 million the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Long-Term Deferred Tax rose 3.27% year-over-year to $253.0 million; the trailing twelve-month figure through Dec 2025 stood at $253.0 million (up 3.27% YoY), and the FY2025 full-year result was $253.0 million, up 3.27% from the prior year.
- Long-Term Deferred Tax improved to $253.0 million in Q4 2025 per IVVD's latest filing, from $244.9 million in the prior quarter.
- Across five years, Long-Term Deferred Tax topped out at $253.0 million in Q4 2025 and bottomed at $201.1 million in Q4 2023.
- Historically, Long-Term Deferred Tax has averaged $233.0 million across 3 years, with a median of $244.9 million in 2024.
- The sharpest annual moves came in 2024 and 2025: Long-Term Deferred Tax increased 21.81% in 2024, then rose 3.27% in 2025.
- Over 3 years, Long-Term Deferred Tax stood at $201.1 million in 2023, then climbed by 21.81% to $244.9 million in 2024, then grew by 3.27% to $253.0 million in 2025.
- According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $253.0 million, $244.9 million, and $201.1 million for Q4 2025, Q4 2024, and Q4 2023 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn |
| 10 | Invivyd | 244.65 Mn | 84.57 Mn | 13.01 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 252.95 Mn |
| Dec 31, 2024 | 244.95 Mn |
| Dec 31, 2023 | 201.08 Mn |